BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 29
• 30
• 31

• 

  GLP-1

  Merck Joins Obesity Pill Race With Up to $2B Hansoh Deal

  The Hansoh deal will let Merck compete in the crowded oral GLP-1 space alongside fellow pharma giants Eli Lilly, Novo Nordisk and Roche.

  December 18, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Manufacturing

  Biopharma’s Big Question of 2024: Can You Scale It?

  Suddenly the hottest thing in biopharma isn’t a new indication, disease target or modality—it’s manufacturing, and all of pharma is going to be vying for capacity and talent.

  December 18, 2024

   · 

  5 min read

   · 

  Annalee Armstrong
• Press Releases

  Akari Therapeutics Announces Key Leadership Appointments

  December 18, 2024

   · 

  9 min read
• Press Releases

  Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

  December 18, 2024

   · 

  5 min read
• Press Releases

  Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model

  December 18, 2024

   · 

  5 min read
• Press Releases

  Remedy Plan Therapeutics Initiates Dosing in Phase 1 Clinical Trial of RPT1G, a First-In-Class Hyperbolic NAMPT Inhibitor

  December 18, 2024

   · 

  2 min read
• Press Releases

  Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

  December 18, 2024

   · 

  9 min read
• Press Releases

  SpinaFX Completes its Series B Funding Round

  December 18, 2024

   · 

  5 min read
• Press Releases

  Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model

  December 18, 2024

   · 

  11 min read
• Press Releases

  Novo Holdings Completes Acquisition of Catalent

  December 18, 2024

   · 

  4 min read